诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展

doi:10.11904/j.issn.1002-3070.2018.04.015

摘要/Abstract

摘要： 越来越多的证据表明,不可控制的炎症与肿瘤发生、发展有着密切的关系,其中慢性炎症可能在包括膀胱癌在内的各种恶性肿瘤中发挥关键作用。膀胱癌是泌尿系统最常见的恶性肿瘤,对于非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术仍是主要手段,但其术后易复发,复发后恶性度逐渐增加,故术后需辅助性药物治疗,降低其复发与进展。如今免疫治疗成为研究热点,并取得较好效果。本文就诱发膀胱癌的常见慢性炎症因素及其免疫治疗相关研究做一简述。

关键词: 膀胱癌, 慢性炎症, 诱发因素, 免疫治疗

Abstract: More and more evidence shows that uncontrollable inflammation has closely associated with tumorigenesis and development.Chronic inflammation may play a key role in various malignant tumors including bladder cancer.Bladder cancer is the most common malignant tumor of the urinary system.For non-muscle-invasive bladder cancer,the main method is still transurethral resection of bladder tumors,but its recurrence after surgery,the degree of malignancy after recurrence is gradually increased,so the need for postoperative adjuvant drug treatment reduces its recurrence and progression.Nowdays,immunotherapy has become a research hotspot and has achieved good effects.This article briefly describes the common chronic inflammation factors that induce bladder cancer and the related progression on immunotherapy.

Key words: Bladder cancer, Chronic inflammation, Inducing factors, Immunotherapy

中图分类号:

R694

孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.

SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.

参考文献

1 Fernandes JV,Cobucci RN,Jatobã CA,et al.The role of the mediators of inflammation in cancer development[J].Pathol Oncol Res,2015,21(3):527-534.
2 Kim HS,Ku JH.Systemic inflammatory response based on neutrophil-to-lymphocyte ratio as a prognostic marker in bladder cancer[J].Dis Markers,2016,2016:8345286.
3 Richards KA,Ham S,Cohn JA,et al.Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the medicare population:implications for sex disparities[J].Int J Urol,2016,23(1):42-47.
4 Jiang X,Castelao JS,Cortessis V,et al.Urinary tract infections and reduced risk of bladder cancer in Los Angeles[J].Br J Cancer,2009,100(5):834-839.
5 Vermeulen SH,Hanum N,Grotenhuis AJ,et al.Recurrent urinary tract infection and risk of bladder cancer in the nijmegen bladder cancer study[J].Br J Cancer,2015,112(3):594-600.
6 Vale N,Gouveia MJ,Rinaldi G,et al.The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer[J].Tumour Biol,2017,39(3):1010428317692247.
7 Botelho MC,Oliveira PA,Lopes C,et al.Schistosoma haematobium total antigen induces dysplasia and inflammation on the urothelium of CD-1 mice[J].Virchows Arch,2009,455(1):66-67.
8 Shams TM,Metawea M,Salim EI.c-KIT positive schistosomal urinary bladder carcinoma are frequent but lack KIT gene mutations[J].Asian Pac J Cancer Prev,2013,14(1):15-20.
9 Thanan R,Murata M,Ma N,et al.Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer[J].Mediators Inflamm,2012,2012(64):165879.
10 Honeycutt J,Hammam O,Hsieh MH.Schistosoma haematobium egg-induced bladder urothelial abnormalities dependent on p53 are modulated by host sex[J].Exp Parasitol,2015,158:55-60.
11 Li N,Yang L,Zhang Y,et al.Human papillomavirus infection and bladder cancer risk:a meta-analysis[J].J Infect Dis,2011,204(2):217-223.
12 Offutt-Powell TN,Ojha RP,Tota JE,et al.Human papillomavirus infection and bladder cancer:an alternate perspective from a modified meta-analysis[J].J Infect Dis,2012,206(3):453-454.
13 Kim SH,Joung JY,Chung J,et al.Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation[J].PLoS One,2014,9(3):e93525.
14 Shigehara K,Kawaguchi S,Sasagawa T,et al.Etiological correlation of human papillomavirus infection in the development of female bladder tumor[J].Apmis,2013,121(12):1169-1176.
15 Network TCGA.Comprehensive molecular characterization of urothelial bladder carcinoma[J].Nature,2014,507(7492):315-322.
16 张征荣,杜均祥,谢云,等.人乳头瘤病毒16/18感染与膀胱癌组织中Rb和p16蛋白表达的相关性分析[J].国际检验医学杂志,2017,38(12):1636-1638.
17 Clouston D,Lawrentschuk N.Metaplastic conditions of the bladder[J].BJU Int,2013,112(Suppl2):27-31.
18 Sui X,Lei L,Chen L,et al.Inflammatory microenvironment in the initiation and progression of bladder cancer[J].Oncotarget,2017,8(54):93279-93294.
19 Ho CH,Sung KC Lim SW,et al.Chronic indwelling urinary catheter increase the risk of bladder cancer,even in patients without spinal cord injury[J].Medicine(Baltimore),2015,94(43):e1736.
20 Husmann DA,Rathbun SR.Long-term follow up of enteric bladder augmentations:the risk for malignancy[J].J Pediatr Urol,2008,4(5):381-385.
21 Higuchi TT,Granberg CF,Fox JA,et al.Augmentation cystoplasty and risk of neoplasia:fact,fiction and controversy[J].J Urol,2010,184(6):2492-2496.
22 Nicastro HL,Grubbs CJ,Margaret JM,et al.Preventive effects of NSAIDs,NO-NSAIDs,and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model[J].Cancer Prev Res,2014,7(2):246-254.
23 Tran HT,Márton MR,Herz C,et al.Nasturtium(Indian cress,Tropaeolum majus nanum)dually blocks the COX and LOX pathway in primary human immune cells[J].Phytomedicine,2016,23(6):611-620.
24 Zhang H,Jiang D,Li X.Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk:a meta-analysis of epidemiologic studies[J].PLoS One,2013,8(7):e70008.
25 王春荣,林宗明,陈耀武.COX-2抑制剂对膀胱肿瘤的抑制作用[J].现代泌尿外科杂志,2009,14(2):110-113.
26 Sabichi AL,Lee JJ,Grossman HB,et al.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer[J].Cancer Prev Res,2011,4(10):1580-1589.
27 Thomas GJ,Morton CA.Cyclooxygenase in cancer prevention and treatments for actinic keratosis[J].Dermatol Ther,2017,7(1):21-29.
28 Redelmansidi G,Glickman MS,Bochner BH.The mechanism of action of BCG therapy for bladder cancer-A current perspective[J].Nat Rev Urol,2014,11(3):153-162.
29 Zeng S,Yu X,Chong M,et al.Low-dose versus standard dose of bacillus calmette-guerin in the treatment of nonmuscle invasive bladder cancer:a systematic review and meta-analysis[J].Medicine,2015,94(49):e2176.
30 Herr HW,Dalbagni G.Intravesical bacille calmette-guérin(BCG)in immunologically compromised patients with bladder cancer[J].BJU Int,2013,111(6):984-987.
31 Gan C,Mostafid H,Khan MS,et al.BCG immunotherapy for bladder cancer-the effects of substrain differences[J].Nat Rev Urol,2013,10(10):580-588.
32 Nesi G,Nobili S,Cai T,et al.Chronic inflammation in urothelial bladder cancer[J].Virchows Arch,2015,467(6):623-633.
33 García-Cuesta EM,López-Cobo S,Álvarez-Maestro M,et al.NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation[J].Front Immunol,2015,8(6):284.
34 Kates M,Nirschl T,Sopko NA,et al.Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer[J].Cancer Immunol Res,2017,5(7):594-603.
35 Smith SG,Koppolu BP,Ravindranathan S,et al.Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer[J].Cancer Immunol Immunother,2015,64(6):689-696.
36 Matsumoto K,Kikuchi E,Horinaga M,et al.Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model[J].Hum Gene Ther,2011,22(11):1423-1432.
37 Newton MR,Askeland EJ,Andresen ED.Anti-interleukin-10R1 monoclonal antibody in combination with bacillus calmette-guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity[J].Clin Exp Immunol,2014,177(1):261-268.
38 Schwartz JC,Zhang X,Fedorov AA,et al.Structural basis for co-stimulation by the human CTLA-4/B7-2 complex[J].Nature,2001,410(6828):604-608.
39 张珉,钟武.黑色素瘤治疗新组合——Nivolumab和Ipilimumab[J].临床药物治疗杂志,2017,15(1):79-84.
40 Comin B,Escuin H,Ibarrondo FJ,et al.Tremelimumab:research and clinical development[J].Onco Targets Ther,2016,23(9):1767-1776.
41 Sui X,Ma J,Han W,et al.The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients[J].Oncotarget,2015,6(23):19393-19404.
42 Farina MS,Lundgren KT,Bellmunt J.Immunotherapy in urothelial cancer:recent results and future perspectives[J].Drugs,2017,77(10):1077-1089.
43 Kurtoglu M,Davarpanah NN,Qin R,et al.Elevating the horizon:emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma[J].Clin Genitourin Cancer,2015,13(5):410-420.

[1]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[2]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[3]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[4]	柳清,尤泊森,马景光,邢丽娜. MicroRNA-30a在膀胱癌中的表达及作用[J]. 实用肿瘤学杂志, 2017, 31(4): 310-315.
[5]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[6]	骆莉萍,吴振启. 羟基喜树碱联合5-氟尿嘧啶于膀胱癌化疗中的疗效及安全性研究[J]. 实用肿瘤学杂志, 2016, 30(4): 300-303.
[7]	张锐, 王智煜, 文孝婷综述, 赵晖审校. 肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 167-171.
[8]	黄娟娟, 王雯欣综述, 曹峰林审校. 血液系统恶性肿瘤细胞免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 61-65.
[9]	全丽娜,刘爱春,郭秀臣,李莲乔,贾垂明. B非霍奇金淋巴瘤患者Th17、Treg水平及Th17/Treg失衡的研究[J]. 实用肿瘤学杂志, 2013, 27(5): 400-405.
[10]	赵丽娜, 全丽娜, 郭秀臣, 刘爱春. 重组鼠CD40配体的Ankara痘病毒疫苗对鼠淋巴瘤的免疫治疗作用的研究[J]. 实用肿瘤学杂志, 2013, 27(4): 308-312.
[11]	张晶岩, 于友涛, 赵宪, 李海斌, 宋浩. 介入联合手术切除及免疫疗法治疗中晚期巨大肾癌[J]. 实用肿瘤学杂志, 2012, 26(6): 519-523.
[12]	武丽华, 王东亮, 张艳桥. 髓源性抑制细胞——肿瘤免疫治疗的新靶点[J]. 实用肿瘤学杂志, 2012, 26(4): 369-372.
[13]	刘艳艳, 王东亮, 张艳桥. 调节性T细胞与恶性肿瘤的过继免疫治疗[J]. 实用肿瘤学杂志, 2012, 26(2): 173-177.
[14]	安旭姝, 雷雪, 李雪. 老年膀胱癌术后发生认知障碍的系统化管理[J]. 实用肿瘤学杂志, 2011, 25(4): 369-371.
[15]	刘高明, 朱莉. 舒适护理在膀胱灌注化疗中的应用[J]. 实用肿瘤学杂志, 2011, 25(4): 372-374.